Compare Lloyds Banking Group Plc American Depositary Shares (LYG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lloyds Banking Group Plc American Depositary Shares vs Tango Therapeutics Inc. — how do they compare? Lloyds Banking Group Plc American Depositary Shares trades at $5.48 (market cap $79.07B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Lloyds Banking Group Plc American Depositary Shares is far larger — about 21.1× Tango Therapeutics Inc.'s market cap, and Lloyds Banking Group Plc American Depositary Shares pays a 3.96% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lloyds Banking Group Plc American Depositary Shares for 3 Days and Tango Therapeutics Inc. for 0 Days on average.
| LYG | TNGX | |
|---|---|---|
Market Cap | $79.07B | $3.75B |
Volume | 20,385,611 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $6.28 | $32.90 |
52-Week Low | $4.44 | $7.50 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $101.61B | $2.77B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lloyds Banking Group (LYG) trades at $5.50, up 0.73% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 24.5% and has beaten earnings estimates in two of the last three quarters. Recent news highlights its 2030 growth plan emphasizing AI and efficiency, with potential acquisition interest in Aldermore.
The outlook is mixed: analyst consensus is bullish (58% buy ratings), but technicals and a recent earnings miss pose near-term risks. Upside catalysts include strategic investments and resilient UK consumers, while risks involve economic sensitivity and competitive pressures. The stock's valuation appears reasonable with a P/E of 12.98.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Lloyds Banking Group Plc American Depositary Shares
Lloyds Banking Group provides retail, commercial, and insurance services in the United Kingdom. Its banking brands include Lloyds Bank, Halifax, and Bank of Scotland.
Read more on LYG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
